Catalent, Inc.
(NYSE : CTLT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
MYOKMyoKardia, Inc. 0.09%223.531.8%$529.51m
HZNPHorizon Therapeutics Plc -3.59%74.935.8%$156.10m
VRXValeant Pharmaceuticals International, Inc. -2.08%16.5014.1%$97.09m
JAZZJazz Pharmaceuticals Plc -1.05%144.102.4%$73.67m
CTLTCatalent, Inc. -1.80%87.782.1%$69.26m
UTHRUnited Therapeutics Corp. 3.06%134.2314.1%$68.71m
BHCBausch Health Cos., Inc. -2.08%16.500.0%$59.77m
SAGESAGE Therapeutics, Inc. -0.72%73.388.6%$45.85m
ICLRICON plc -1.62%180.304.2%$42.06m
ARGXargenx SE -2.46%248.130.0%$35.01m
PRGOPerrigo Co. Plc 3.08%43.846.8%$32.61m
ENDPEndo International Plc -3.38%4.578.7%$30.02m
GWPHGW Pharmaceuticals Plc 0.76%90.016.2%$28.78m
AMRNAmarin Corp. Plc -1.22%4.861.5%$26.85m
ICPTIntercept Pharmaceuticals, Inc. -3.97%27.7916.8%$23.24m

Company Profile

Catalent, Inc. operates as a holding company. The firm engages in the provision of delivery technologies and development solutions for drugs, biologics and consumer and animal health products. It operates through the following segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery and Clinical Supply Services. The Softgel Technologies segment formulates, develops and manufactures services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufactures services for blow-fill-seal unit doses, prefilled syringes, vials and cartridges, analytical development and testing services for large molecules, inhaled products for delivery via metered dose inhalers, dry powder inhalers and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution and inventory management for drugs and biologics in clinical trials. The company was founded in April 2007 and is headquartered in Somerset, NJ.